Boehringer Accelerates Adalimumab Dual Pricing Strategy With 81% Discount
Adds Deep-Discounted Unbranded Version Of Cyltezo Biosimilar Rival To Humira In The US
Boehringer Ingelheim says it is pushing ahead with an earlier than expected launch of a deep-discounted unbranded version of its Cyltezo adalimumab biosimilar in the US, as it looks to compete with other Humira rivals.
